Real-world study identifies optimal metric to assess prostate cancer treatment response

A real-world study has identified what researchers believe is the optimal metric to determine the effectiveness of therapy for metastatic castration-sensitive prostate cancer.Patients whose PSA levels dropped below 0.2 ng/mL within 9 months of treatment initiation exhibited 54% lower risk for death than patients whose PSA did not fall below that level, a retrospective analysis of Veterans Health